Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

EVP Beats Cisplatin for Resectable MIBC

2.

Can taking vitamin D supplements every day lower the mortality rate from cancer?

3.

In prostate cancer survivorship, sleep disturbances are underappreciated.

4.

A single-cell analysis reveals a distinctive immunosuppressive tumor microenvironment in kidney cancer brain metastases.

5.

Specialist Referrals Are Critical for Functional High-Risk Multiple Myeloma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot